H.C. Wainwright reiterates Faeth Therapeutics stock rating at buy

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after Phase 2 trial results. The trial showed a 33% response rate and 7.4-month median progression-free survival. FTH shares have fallen 41% since the pre-announcement close, trading at $12.92.

Original reporting
Published Nov 11, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$FTH
Bullish
high confidence
Mentioned
$FTH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FTHBullishMed
01

Why it matters

The reiteration of a Buy rating and a $60 target reflects confidence in the trial data, likely prompting short‑term buying interest.

02

Market read

First‑report Phase 2 results provide a fresh catalyst for FTH, with potential spillover to similar biotech stocks.

03

What to watch

Potential regulatory delays and competition from other endometrial cancer therapies could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Faeth Therapeutics (FTH) is a clinical‑stage biotech focused on PI3K/AKT/mTOR inhibitors. The PIK-201 trial is a key milestone before advancing to Phase 3.

Company-level read

Ticker impact

$FTHBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating with a $60 price target after Faeth Therapeutics reported Phase 2 PIK-201 trial results showing 33% response rate.

Expected impact

likely upward pressure as investors price in the encouraging trial outcomes and higher target price.

Evidence & confidence

The trial results exceed benchmarks and multiple analysts raised targets, indicating a material catalyst for the stock.

Market effects

The data may lift sentiment across the biotech sector, especially other PI3K/AKT/mTOR pathway developers.

Limited to U.S. biotech investors; no broader regional effect.

Modest global relevance, primarily affecting U.S. and international biotech funds.

Counterpoint

The trial size is small and long-term efficacy remains uncertain; the stock could face volatility if Phase 3 fails.

Key entities

  • Faeth Therapeutics

    Biotech company developing PIKTOR combination therapy.

  • H.C. Wainwright

    Equity research firm that reiterated a Buy rating on FTH.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.